All these considerations, along with the high tumor heterogeneity in NSCLC, could explain the differences between the two studies and why dynamic protein levels of PD-L1 could be a better predictive biomarker than tissue PD-L1 and a better strategy than evaluating mRNA PD-L1expression. This evidence concerns the gene CD274 and non-small cell lung carcinoma.